<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681586</url>
  </required_header>
  <id_info>
    <org_study_id>AP18005ONB</org_study_id>
    <nct_id>NCT04681586</nct_id>
  </id_info>
  <brief_title>Bright Light Therapy as Possible Treatment Option for MS-Fatigue</brief_title>
  <official_title>Bright Light Therapy as Possible Treatment Option for Fatigue in Multiple Sclerosis Patients - A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Bank of Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effect of a 2-week trial of bright light therapy (BLT,&#xD;
      10.000 lx) on fatigue in multiple sclerosis (MS) patients. In this randomised&#xD;
      placebo-controlled trial, the effect of bright light therapy will be compared to dim red&#xD;
      light. MS-fatigue is quantified by patients using a visual analogue scale (VAS) and activity&#xD;
      levels, subjective and objective sleep parameters and daytime sleepiness are measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Materials and methods:&#xD;
&#xD;
        -  visual analogue scale (4x/day for 6 weeks; measuring fatigue)&#xD;
&#xD;
        -  wrist actigraphy (6 weeks)&#xD;
&#xD;
        -  sleep diaries (6 weeks)&#xD;
&#xD;
        -  polysomnography (2x)&#xD;
&#xD;
        -  multiple sleep latency test (2x)&#xD;
&#xD;
        -  4 subtests of the TAP (Testbatterie zur Aufmerksamkeitsprüfung; Alertness, Vigilance,&#xD;
           Go/No-Go, Split Attention)&#xD;
&#xD;
        -  questionnaires (Fatigue Severity Scale, Epworth Sleepiness Scale, Pittsburgh Sleep&#xD;
           Quality Index, Beck Depression Inventory, Beck Anxiety Inventory, Modified Fatigue&#xD;
           Impact Scale, Morningness-Eveningness Questionnaire)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fatigue levels</measure>
    <time_frame>Day 1, Day 14, Day 30, Day 46</time_frame>
    <description>Improvement of MS-fatigue symptoms as measured with questionnaires (Fatigue Severity Scale; FSS, Modified Fatigue Impact Scale; MFIS and a visual analogue scale)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fatigue levels</measure>
    <time_frame>Day 15, Day 31</time_frame>
    <description>Improvement of MS-fatigue symptoms as measured with psychological testing (Testbatterie zur Aufmerksamkeitsprüfung; TAP)</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in nighttime sleep</measure>
    <time_frame>Day 14, Day 30</time_frame>
    <description>Improvement in nighttime sleep as measured with polysomnography (PSG)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in daytime sleepiness</measure>
    <time_frame>Day 15, Day 31</time_frame>
    <description>Improvement of sxcessive daytime sleepiness as measured using a multiple sleep latency test (MSLT) and Epworth Sleepiness Scale (ESS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in activity levels</measure>
    <time_frame>Day 1 through day 46</time_frame>
    <description>Rapprochement of activity levels according to circadian rhythms</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in psychological well-being</measure>
    <time_frame>Day 1, Day 14, Day 30, Day 46</time_frame>
    <description>Improvement in depression and anxiety scores as measured by Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Bright white light</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dim red light</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bright light therapy</intervention_name>
    <description>using a bright light therapy device (10.000 lux) for 30min every morning for two weeks</description>
    <arm_group_label>Bright white light</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>dim red light</intervention_name>
    <description>using the same device as the active group, but with an installed filter that dims light to &lt;300 lux for 30min every morning for two weeks</description>
    <arm_group_label>Dim red light</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MS patients who suffer from fatigue&#xD;
&#xD;
          -  Age between 18 and 65 years old&#xD;
&#xD;
          -  FSS Score of 36 or greater&#xD;
&#xD;
          -  ESS Score of 12 or greater&#xD;
&#xD;
          -  MEQ Score between 31 and 69&#xD;
&#xD;
          -  BDI Score lower than 19&#xD;
&#xD;
          -  BAI Score lower than 27&#xD;
&#xD;
          -  EDSS lower than 4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  sleep disorders (periodic limb movement disorders, obstructive or central sleep apnea,&#xD;
             REM sleep behavior disorders)&#xD;
&#xD;
          -  change of antidepressive/fatigue influencing/sleep influencing/photosensizing/MS&#xD;
             medication within the preceding 4 weeks&#xD;
&#xD;
          -  clinical MS-relapse within the preceding 4 weeks&#xD;
&#xD;
          -  consumption of alcohol: more than 1 glass per day&#xD;
&#xD;
          -  consumption of caffeine: more than 4 cups per day&#xD;
&#xD;
          -  current shift work&#xD;
&#xD;
          -  Jet lag (travelled across two or more time zones within 90 days before study screening&#xD;
&#xD;
          -  Retinopathy or other visual diseases/abnormalties&#xD;
&#xD;
          -  Traumatic brain injury within the preceding 5 years&#xD;
&#xD;
          -  pregnant or lactating&#xD;
&#xD;
          -  Participation in another clinical trial at the same time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefan Seidel, MD</last_name>
    <phone>0043 1 40 400 34280</phone>
    <email>stefan.seidel@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Voggenberger, MSc</last_name>
    <phone>0043 1 40 400 34280</phone>
    <email>lisa.voggenberger@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Seidel, MD</last_name>
      <phone>0043 1 40 400 34280</phone>
      <email>stefan.seidel@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 19, 2020</last_update_submitted>
  <last_update_submitted_qc>December 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Stefan Seidel</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>bright light therapy</keyword>
  <keyword>MS-Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

